UK's research assessment signals change

7 May 2006

New criteria for allocating public research funds in the UK are the subjects of a government consultation exercise to be launched in May. The existing methodology: the Research Assessment Exercise is to end in 2008 after more than 20 years of operation.

According to the British Medical Journal, which is running a series of discussion articles on the subject over the coming weeks, many academics "will welcome an end to the tyranny of the RAE." Although it has concentrated funds within selected high performing institutions, as intended by successive UK governments, this has been costly in terms of distorting the research agenda in a safe, mainstream direction. More risky and multidisciplinary research where results may not be apparent for a longer period are at a considered to be at a disadvantage.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight